Markets2 min read

Cannabis Telehealth Firm Veri Medtech Targets Nasdaq via $15M Offering

Veri Medtech launches $15M public offering at $4 per share to fund Nasdaq uplisting ambitions in expanding cannabis telehealth sector.

May 11, 2026 at 11:42 AMCannabismarketcap

Cannabis telehealth operator Veri Medtech launches a $15 million public offering, pricing 3.75 million common shares at $4 each as the company pursues a coveted Nasdaq uplisting. The move positions Veri to capitalize on growing investor appetite for cannabis technology plays while accessing deeper capital pools available to major exchange listings.

The telehealth sector within cannabis continues attracting institutional attention as regulatory barriers ease across key markets. Veri's uplisting strategy mirrors successful transitions by other cannabis operators seeking to shed over-the-counter trading limitations and attract institutional investment flows. The $4 pricing suggests management confidence in current valuation metrics despite broader cannabis sector volatility.

Telehealth platforms gain traction as states expand medical cannabis programs and patients seek convenient access to certifying physicians. The sector benefits from recurring revenue models and lower operational overhead compared to traditional cannabis cultivation or retail operations. Veri's capital raise timing coincides with increased M&A activity in cannabis technology, where strategic buyers target scalable software platforms.

Nasdaq uplisting requirements include minimum bid prices, market capitalization thresholds, and enhanced financial reporting standards. The offering proceeds likely fund compliance infrastructure and working capital needed to meet these benchmarks. Success would provide Veri access to institutional investors currently restricted from OTC cannabis investments by internal mandates.

The cannabis telehealth market faces intensifying competition as traditional telemedicine giants explore cannabis verticals and existing operators expand geographic footprints. Veri's uplisting pursuit reflects broader industry maturation, where companies prioritize institutional legitimacy over rapid growth-at-any-cost strategies that dominated earlier market phases.